Silexion Therapeutics Corp has 14 Schedule 13D or 13G filings on record since 2025-09-15. 2 holders' latest filing reports 5% or more of ordinary shares, par value $0.0135 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Moringa Sponsor, LP | 25% | 1,391,790 | SCHEDULE 13D/A, 2026-08-19 | 2026-07-30 |
| Lincoln Alternative Strategies LLC | 6.18% | 131,250 | SCHEDULE 13G, 2025-09-15 | 2025-09-12 |
| Mitchell P. Kopin | 4.99% | 286,866 | SCHEDULE 13G, 2026-08-18 | 2026-08-11 |
| Lind Global Fund III LP | 4.96% | 212,500 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Orca Capital AG | 4.9% | 109,432 | SCHEDULE 13G/A, 2025-09-15 | 2025-09-11 |
Purpose of Transaction (Item 4)
Moringa Sponsor, LP
The information contained in Item 3 is incorporated by reference in its entirety into this Item 4. On June 22, 2026, Moringa Sponsor, LP filed a claim against Silexion Therapeutics Corp and two of its senior officers (the "Claim"), alleging deliberate and systematic breaches of the Amended and Restated Promissory Note, dated August 15, 2024 (the "Note"). In the Claim, Moringa Sponsor, LP alleges, among other things, that Silexion breached the conditions governing conversion of indebtedness under the Note, including by failing to use the correct share price for conversions, failing to provide the required prior notice, effecting conversions below the minimum amount, and failing to deliver the shares within the required timeframe. Moringa Sponsor, LP seeks a declaration that the purported conversions are void, a determination that an Event of Default has occurred entitling it to immediate repayment of the entire outstanding debt, and, in the alternative, an order correcting the conversions and awarding damages.Item 4 of the SCHEDULE 13D/A filed 2026-08-19
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-15 | Lincoln Alternative Strategies LLC | 6.18% | SCHEDULE 13G |
| 2025-09-15 | Orca Capital AG | 6.2% | SCHEDULE 13G |
| 2025-09-15 | Orca Capital AG | 4.9% | SCHEDULE 13G/A |
| 2025-09-17 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2025-09-18 | Lind Global Fund III LP | 9.9% | SCHEDULE 13G |
| 2025-09-23 | Moringa Sponsor, LP | 14.67% | SCHEDULE 13D/A |
| 2025-11-14 | Lind Global Fund III LP | 6.4% | SCHEDULE 13G/A |
| 2026-02-13 | Mitchell P. Kopin | 9.4% | SCHEDULE 13G/A |
| 2026-05-15 | Lind Global Fund III LP | 4.96% | SCHEDULE 13G/A |
| 2026-05-29 | Moringa Sponsor, LP | 32.99% | SCHEDULE 13D/A |
| 2026-06-23 | Moringa Sponsor, LP | 10.6% | SCHEDULE 13D/A |
| 2026-08-13 | Mitchell P. Kopin | 0% | SCHEDULE 13G/A |
| 2026-08-18 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-08-19 | Moringa Sponsor, LP | 25% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Silexion Therapeutics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.